The Pillar Biosciences leadership team consists of professionals experienced in developing and launching precision NGS panels accessible to the high-throughput specialty NGS laboratory.
Gang Song PhD
Founder and Chief Executive Officer
Dr. Gang Song is the founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp® technology. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company. Previously, Dr. Song was a Technical Lead at Integrated Genetics, LabCorp (previously Genzyme Genetics), and prior to that, was a Project Lead at IQuum before its acquisition by Roche Molecular Diagnostics. Dr. Song completed his postdoctoral training in Timothy Springer's lab at Harvard Medical School and received his PhD from Shanghai Medical College of Fudan University, China.
Zhaohui Wang PhD
Co-founder and Chief Science Officer
Dr. Zhaohui Wang co-founded Pillar Biosciences, and co-invented SLIMamp technology. Formerly, she was an Associate Vice President at Integrated Genetics in the genomics laboratory at Laboratory Corporation of America (previously Genzyme Genetics). Prior to LabCorp, Dr. Wang was a group leader at IQuum (now Roche Molecular Diagnostics). Dr. Wang received her PhD in Cellular and Molecular Biology at the University of Massachusetts, Amherst and her undergraduate degree from Peking University, China.
Manfred Scholz PhD, MBA
Chief Commercial Officer
Dr. Manfred Scholz has more than 30 years of clinical diagnostics experience. His strategic and operational management experience includes serving as CEO at Prolias LLC, and President and COO at Stem Cell Preservation Technologies. He was also VP Business Development at IQuum (now Roche Molecular Diagnostics), Senior Director of Business Development at Large Scale Biology, and held various roles at Boston Biomedical Consultants and Dade Behring (now Siemens). Dr. Scholz was a research fellow at the Max-Planck Institute for Biophysics and Harvard University. He received a PhD in Physics from Goethe University in Frankfurt, Germany, and an MBA from Babson College.
Martin Zillmann PhD
Chief Operating Officer
Dr. Martin Zillmann, Pillar Biosciences' Chief Operating Officer, has a long history in nucleic acid diagnostics that started with his role as Director of Assay Development at Variagenics, a pioneer in the field of personalized medicine. Most recently, he served as Head of the Technology Office for the Process Solutions business of MilliporeSigma. Dr. Zillmann holds a PhD in Biochemistry from Rice University and received his undergraduate education from Indiana University.